PolyPeptide Group AG (SWX:PPGN)

Market Cap	862.73M
Revenue (ttm)	344.49M
Net Income (ttm)	-32.42M
Shares Out	32.99M
EPS (ttm)	-0.97
PE Ratio	n/a
Forward PE	881.84
Dividend	n/a
Ex-Dividend Date	n/a

Volume	77,600
Average Volume	38,162
Open	27.60
Previous Close	26.15
Day's Range	27.25 - 29.00
52-Week Range	13.22 - 35.80
Beta	1.07
RSI	67.84
Earnings Date	Aug 12, 2025

About PolyPeptide Group AG

PolyPeptide Group AG operates as a contract development and manufacturing company in Europe, the United States, and India. It develops and manufactures synthetic peptides and oligonucleotides used as active pharmaceutical ingredients or intermediates in therapeutic products for pharmaceutical and biotech companies. The company offers portfolio of drug therapies for metabolic diseases, including the GLP-1. It also provides generic peptides and peptides used in cosmetics, animal health, and medical devices. PolyPeptide Group AG was founded in 195...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1952
• Employees: 1,362
• Stock Exchange: SIX Swiss Exchange
• Ticker Symbol: PPGN

Financial Performance

In 2024, PolyPeptide Group AG's revenue was 336.79 million, an increase of 5.13% compared to the previous year's 320.37 million. Losses were -19.56 million, -61.97% less than in 2023.

Financial numbers in EUR